Improved outcome for very elderly patients with diff use large B-cell lymphoma in the immunochemotherapy era

Leukemia and Lymphoma

Volumn 53, Issue 3, 2012, Pages 394-399

  Hasselblom, Sverker ^a   Stenson, Martin ^a   Werlenius, Olle ^a   Sender, Monica ^a   Lewerin, Catharina ^a   Hansson, Ulrika ^a   Nilsson Ehle, Herman ^a   Andersson, Per Ola ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

80 years; Diffuse large B cell lymphoma; R CHOP; Very elderly

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINBLASTINE; VINCRISTINE;

AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CONFUSION; DRUG RESPONSE; FEMALE; HEART INFARCTION; HUMAN; INFECTIOUS COMPLICATION; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEPTICEMIA; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; KAPLAN-MEIER ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MITOXANTRONE; PALLIATIVE CARE; PREDNISOLONE; PREDNISONE; PROGNOSIS; RADIOTHERAPY, ADJUVANT; REGISTRIES; RETROSPECTIVE STUDIES; SWEDEN; TREATMENT OUTCOME; VINCRISTINE;

EID: 84857590253     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.616612     Document Type: Article

References (23)

1. H asselblom S, Ridell B, Nilsson-Ehle H., et al. Th e impact of gender, age and patient selection on prognosis and outcome in diff use large B-cell lymphoma - a population-based study. Leuk Lymphoma 2007;48:736-745. (Pubitemid 46605546)
2. K rol AD, le Cessie S, Snijder S., et al. Non-Hodgkins lymphoma in the Netherlands: Results from a population-based registry. Leuk Lymphoma 2003;44:451-458. (Pubitemid 36113888)
3. A predictive model for aggressive non-Hodgkins lymphoma. Th e International Non-Hodgkins Lymphoma Prognostic Factors Project. N Eng J Med 1993;329:987-994.
4. K ouroukis CT, Browman GP, Esmail R., et al. Chemotherapy for older patients with newly diagnosed, advanced-stage, aggressivehistology non-Hodgkin lymphoma: A systematic review. Ann Intern Med 2002;136:144-152. (Pubitemid 34073939)
5. P eters FP, Fickers MM, Erdkamp FL., et al. Th e eff ect of optimal treatment on elderly patients with aggressive non-Hodgkins lymphoma: more patients treated with unaff ected response rates. Ann. Hematol. 2001;80:406-410. (Pubitemid 32725458)
6. Coiffi er B, Lepage E, Briere J., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diff use large-B-cell lymphoma. N Eng J Med 2002;346:235-242. (Pubitemid 34438862)
7. Coiffi er B, Th ieblemont C, Van Den Neste E., et al. Long-term outcome of patients in the LNH-98.5 trial, the fi rst randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010;116:2040-2045.
8. B airey O, Benjamini O, Blickstein D., et al. Non-Hodgkins lymphoma in patients 80 years of age or older. Ann. Oncol. 2006;17:928-934. (Pubitemid 43778982)
9. Th ieblemont C, Grossoeuvre A, Houot R., et al. Non-Hodgkins lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome. Ann. Oncol. 2008;19:774-779. (Pubitemid 351461051)
10. S ehn LH, Donaldson J, Chhanabhai M., et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diff use large B-cell lymphoma in British Columbia. J. Clin. Oncol. 2005;23:5027-5033. (Pubitemid 46224009)
11. P eyrade F, Jardin F, Th ieblemont C., et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diff use large B-cell lymphoma: A multicentre, single-arm, phase 2 trial. Lancet Oncol 2011;12:460-468.
12. W eidmann E, Neumann A, Fauth F., et al. Phase II study of bendamustine in combination with rituximab as fi rst-line treatment in patients 80 years or older with aggressive B-cell lymphomas. Ann. Oncol. 2011;22:1839-1844.
13. L ister TA, Crowther D, Sutcliff e SB., et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkins disease: Cotswolds meeting. J. Clin. Oncol. 1989;7:1630-1636. (Pubitemid 19272832)
14. H ryniuk WM, Goodyear M. Th e calculation of received dose intensity. J. Clin. Oncol. 1990;8:1935-1937.
15. Cheson BD, Horning SJ, Coiffi er B., et al. Report of an international workshop to standardize response criteria for non-Hodgkins lymphomas. NCI Sponsored International Working Group. J. Clin. Oncol. 1999;17:1244.
16. O sby E, Hagberg H, Kvaloy S., et al. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaff ected by fi lgrastim treatment: Results of a Nordic Lymphoma Group randomized trial. Blood 2003;101:3840-3848. (Pubitemid 36857855)
17. J anssen-Heijnen ML, van Spronsen DJ, Lemmens VE., et al. A population-based study of severity of comorbidity among patients with non-Hodgkins lymphoma: Prognostic impact independent of International Prognostic Index. Br. J. Haematol. 2005;129:597-606. (Pubitemid 40825820)
18. M oller MB, Pedersen NT, Christensen BE. Diff use large B-cell lymphoma: Clinical implications of extranodal versus nodal presentation-a population-based study of 1575 cases. Br. J. Haematol. 2004;124:151-159. (Pubitemid 38122186)
19. Steen B. Th e elderly yesterday, today and tomorrow: Aspects on cohort diff erences from the gerontological and geriatric population studies in Goteborg, Sweden (H70). Arch Gerontol Geriatr Suppl 2002;8:359-370. (Pubitemid 36194413)
20. Ahlblom A, Drefahl S, Lundstrom H. [Th e aging population. Continuing increase of average longevity is a controversial and exciting question]. Lakartidningen 2010;107:3048-3051.
21. Italiano A, Jardin F, Peyrade F., et al. Adapted CHOP plus rituximab in non-Hodgkins lymphoma in patients over 80 years old. Haematologica 2005;90:1281-1283. (Pubitemid 41375292)
22. P freundschuh M. How I treat elderly patients with diff use large B-cell lymphoma. Blood 2010;116:5103-5110.
23. H ainsworth JD, Flinn IW, Spigel DR., et al. Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diff use large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: A phase II trial of the Sarah Cannon Oncology Research Consortium. Clin Lymphoma Myeloma Leuk 2010;10:44-50.